Charles River Labs SVP Michael Knell sells $1.73m in stock By Investing.com

Michael Knell, Senior Vice President, Finance and Chief Accounting Officer at CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (), sold a total of 6,645 shares of the company’s common stock on August 6, 2026. The transactions amounted to approximately $1,730,249, with sales executed at prices ranging from $258.53 to $265.17 per share. The sale comes as Charles River stock trades near its InvestingPro 52-week high of $277.07, following an impressive 86% return over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value—one of 13 key ProTips available to subscribers.

On the same date, Mr. Knell also acquired 2,345 shares of common stock through the exercise of stock options. These acquisitions totaled approximately $459,909, with exercise prices ranging from $179.66 to $208.44 per share.

Following these reported transactions, Mr. Knell directly holds 11,852 shares of Charles River Laboratories International common stock.

In other recent news, Charles River Laboratories International reported second-quarter 2026 earnings and revenue that surpassed Wall Street expectations. The company posted adjusted earnings per share of $3.02, exceeding the forecast of $2.74, while revenue reached $1 billion, above the anticipated $976.13 million. Following these results, Charles River Labs also raised its full-year outlook. Analyst firms have responded positively to these developments. TD Cowen increased its price target for the company to $300 from $235, highlighting strong preclinical demand. JPMorgan upgraded the stock rating to Overweight from Neutral and raised its price target to $310, citing impressive booking metrics. Evercore ISI also raised its price target to $300, noting the company’s first quarter of organic revenue growth since the third quarter of 2023. These upgrades reflect a growing confidence in Charles River Labs’ performance and future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.